Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab
Follows Earlier License And Supply Agreement For Golimumab Biosimilar
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
You may also be interested in...
Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Bio-Thera And Intract Partner For Oral mAb Project
Chinese biosimilars specialist Bio-Thera Solutions has struck a licensing deal with Intract Pharma that will give it access to drug delivery technologies that will be used to develop novel oral monoclonal antibody treatments for gastrointestinal inflammatory indications.